ADY Stock Overview Provides healthcare services in the United States. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Amedisys, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Amedisys Historical stock prices Current Share Price US$87.00 52 Week High US$90.50 52 Week Low US$78.50 Beta 0.73 1 Month Change -0.57% 3 Month Change 1.75% 1 Year Change 2.35% 3 Year Change -38.73% 5 Year Change -41.61% Change since IPO 406.77%
Recent News & Updates
Amedisys, Inc. Reports Impairment Charges for the Fourth Quarter Ended December 31, 2024 Mar 01
Amedisys, Inc. Reports Impairment Charges for the Fourth Quarter Ended December 31, 2024 Feb 28
Amedisys, Inc., Annual General Meeting, Dec 30, 2024 Dec 11
Third quarter 2024 earnings released: EPS: US$0.52 (vs US$0.80 in 3Q 2023) Nov 08
Michael P. North Leaves Amedisys, Inc. as Chief Information Officer and Compensation Committee of the Board of Directors, Effective August 31, 2024 Aug 23
Second quarter 2024 earnings released: EPS: US$0.99 (vs US$2.46 loss in 2Q 2023) Jul 25 See more updates
Amedisys, Inc. Reports Impairment Charges for the Fourth Quarter Ended December 31, 2024 Mar 01
Amedisys, Inc. Reports Impairment Charges for the Fourth Quarter Ended December 31, 2024 Feb 28
Amedisys, Inc., Annual General Meeting, Dec 30, 2024 Dec 11
Third quarter 2024 earnings released: EPS: US$0.52 (vs US$0.80 in 3Q 2023) Nov 08
Michael P. North Leaves Amedisys, Inc. as Chief Information Officer and Compensation Committee of the Board of Directors, Effective August 31, 2024 Aug 23
Second quarter 2024 earnings released: EPS: US$0.99 (vs US$2.46 loss in 2Q 2023) Jul 25
First quarter 2024 earnings released: EPS: US$0.44 (vs US$0.78 in 1Q 2023) Apr 25
Full year 2023 earnings released: US$0.30 loss per share (vs US$3.65 profit in FY 2022) Feb 22
Insufficient new directors Jan 01
Third quarter 2023 earnings released: EPS: US$0.80 (vs US$0.79 in 3Q 2022) Oct 25 Option Care Health, Inc. (NasdaqGS:OPCH) cancelled the acquisition of Amedisys, Inc. (NasdaqGS:AMED). Jun 27
Investor sentiment improves as stock rises 18% Jun 07 Option Care Health, Inc. (NasdaqGS:OPCH) entered into an agreement and plan of merger to acquire Amedisys, Inc. (NasdaqGS:AMED) for $3.2 billion. May 05
First quarter 2023 earnings released: EPS: US$0.78 (vs US$0.97 in 1Q 2022) May 04
Full year 2022 earnings released: EPS: US$3.65 (vs US$6.41 in FY 2021) Feb 17
Amedisys, Inc. (NasdaqGS:AMED) announces an Equity Buyback for $100 million worth of its shares. Feb 10
Amedisys, Inc. to Report Q4, 2022 Results on Feb 15, 2023 Jan 31
Now 21% undervalued after recent price drop Dec 21
Insufficient new directors Dec 02
Amedisys, Inc. Names Scott Ginn as Acting Chief Operating Officer Nov 23 Amedisys, Inc. Announces CEO Changes
High number of new directors Nov 16
Amedisys, Inc. Provides Earnings Guidance for the Year 2022 Oct 29
Third quarter 2022 earnings released: EPS: US$0.79 (vs US$1.38 in 3Q 2021) Oct 27
Amedisys, Inc. to Report Q3, 2022 Results on Oct 26, 2022 Oct 19
Amedisys, Inc. Announces Resignation of David L. Kemmerly as Chief Legal and Government Affairs Officer Sep 24
Second quarter 2022 earnings released: EPS: US$0.91 (vs US$2.46 in 2Q 2021) Jul 28
Amedisys, Inc. to Report Q2, 2022 Results on Jul 27, 2022 Jul 07 Amedisys, Inc.(NasdaqGS:AMED) dropped from Russell 1000 Growth-Defensive Index
First quarter 2022 earnings released: EPS: US$0.97 (vs US$1.52 in 1Q 2021) Apr 28
High number of new directors Apr 27
Amedisys, Inc. Announces Promotion of Nick Muscato as Chief Strategy Officer Apr 27
Amedisys, Inc. to Report Q1, 2022 Results on Apr 27, 2022 Apr 14 Amedisys, Inc. (NasdaqGS:AMED) completed the acquisition of Assets of AssistedCare Home Health, Inc. and RH Homecare Services, LLC.
Amedisys, Inc. Announces Resignation of Richard A. Lechleiter from the Board of Directors Mar 07
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Feb 24
Amedisys, Inc. (NasdaqGS:AMED) signed a definitive agreement to acquire Assets of AssistedCare Home Health, Inc. Feb 24
Amedisys, Inc. (NasdaqGS : AMED) agreed to acquire Evolution Health, LLC from Emergency Medical Services LP Corporation. Feb 03
Amedisys, Inc. to Report Q4, 2021 Results on Feb 23, 2022 Feb 01
High number of new directors Jan 11
Investor sentiment improved over the past week Dec 11
Lead Independent Director recently bought €125k worth of stock Dec 05
Third quarter 2021 earnings released: EPS US$1.38 (vs US$2.20 in 3Q 2020) Nov 03
Independent Director recently sold €1.8m worth of stock Sep 05
Investor sentiment deteriorated over the past week Aug 06
Second quarter 2021 earnings released: EPS US$2.46 (vs US$1.07 in 2Q 2020) Aug 05
President & COO recently sold €64k worth of stock Jul 09
Amedisys, Inc. (NasdaqGS:AMED) entered into an Agreement to acquire Contessa Health, Inc. for $250 million. Jul 01
Amedisys, Inc. (NasdaqGS:AMED) entered into a definitive agreement to acquire Home Health and Hospice Operations of Visiting Nurse Association. May 12
Insider recently sold €420k worth of stock May 02
First quarter 2021 earnings released: EPS US$1.52 (vs US$0.98 in 1Q 2020) May 01
Amedisys, Inc. Provides Revenue Guidance for the Full Year 2021 Apr 30
Amedisys, Inc. and Sound Physicians to Launch Home Health Advanced Pilot Program Apr 29
New 90-day low: €195 Mar 06
Independent Director recently bought €215k worth of stock Mar 06
Full year 2020 earnings released: EPS US$5.64 (vs US$3.95 in FY 2019) Feb 26
Revenue misses expectations Feb 26
Amedisys, Inc. Announces Executive Changes Feb 26
Amedisys, Inc. Announces Executive Changes Feb 25
Amedisys, Inc. to Report Q4, 2020 Results on Feb 24, 2021 Feb 10
Amedisys, Inc.(NasdaqGS:AMED) dropped from Russell 2000 Dynamic Index Jan 28
New 90-day high: €254 Jan 23
New 90-day high: €242 Jan 08
Amedisys, Inc. and Option Care Health Inc. Collaborate to Provide Innovative COVID Therapy Access Model Jan 06
New 90-day high: €236 Dec 22
Ivanetta Davis Samuels Joins Amedisys, Inc.'s Board of Director Dec 16
New 90-day high: €228 Nov 02
Third-quarter earnings released: Revenue beats expectations Oct 30
Third quarter earnings released Oct 30
Amedisys, Inc. to Report Q3, 2020 Results on Oct 28, 2020 Oct 14
New 90-day high: €214 Oct 13
New 90-day high - €204 Aug 25
New 90-day high - €200 Aug 07
Amedisys, Inc. to Report Q2, 2020 Results on Jul 28, 2020 Jul 18
Amedisys, Inc.(NasdaqGS:AMED) dropped from Russell 2000 Growth-Defensive Index Jul 04 Amedisys, Inc.(NasdaqGS:AMED) dropped from Russell 2000 Defensive Index Shareholder Returns ADY DE Healthcare DE Market 7D 1.8% 4.8% 0.9% 1Y 2.4% 38.5% 14.4%
See full shareholder returns
Return vs Market: ADY underperformed the German Market which returned 14.4% over the past year.
Price Volatility Is ADY's price volatile compared to industry and market? ADY volatility ADY Average Weekly Movement 3.4% Healthcare Industry Average Movement 4.8% Market Average Movement 4.8% 10% most volatile stocks in DE Market 11.2% 10% least volatile stocks in DE Market 2.6%
Stable Share Price: ADY has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: ADY's weekly volatility (3%) has been stable over the past year.
About the Company Amedisys, Inc., together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.
Show more Amedisys, Inc. Fundamentals Summary How do Amedisys's earnings and revenue compare to its market cap? ADY fundamental statistics Market cap €3.40b Earnings (TTM ) €41.68m Revenue (TTM ) €2.26b
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) ADY income statement (TTM ) Revenue US$2.35b Cost of Revenue US$1.33b Gross Profit US$1.02b Other Expenses US$974.65m Earnings US$43.23m
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/03/02 12:43 End of Day Share Price 2025/02/28 00:00 Earnings 2024/12/31 Annual Earnings 2024/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github .
Analyst Sources Amedisys, Inc. is covered by 31 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Brian Hoffman Avondale Partners Matthew Gillmor Baird Steven Valiquette Barclays
Show 28 more analysts 
